Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing

EMBO Mol Med. 2018 Jun;10(6):e8454. doi: 10.15252/emmm.201708454.

Abstract

Regular blood transfusion is the cornerstone of care for patients with red blood cell (RBC) disorders such as thalassaemia or sickle-cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR-mediated genome editing of an immortalised human erythroblast cell line (BEL-A) to generate multiple enucleation competent cell lines deficient in individual blood groups. Edits are combined to generate a single cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull), Kell (K0), Duffy (Fynull), GPB (S-s-U-). These cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof-of-principle demonstration of combinatorial CRISPR-mediated blood group gene editing to generate customisable or multi-compatible RBCs for diagnostic reagents or recipients with complicated matching requirements.

Keywords: CRISPR; BEL‐A; erythroid; transfusion; universal donor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Group Antigens / genetics
  • Blood Group Incompatibility / genetics*
  • Cell Line
  • Clustered Regularly Interspaced Short Palindromic Repeats / genetics*
  • Erythrocyte Transfusion*
  • Gene Editing / methods*
  • Gene Knockout Techniques
  • Humans
  • Proof of Concept Study

Substances

  • Blood Group Antigens